Europese Unie - IJslands - EMA (European Medicines Agency)

mylan pharmaceuticals limited - fulvestrant - brjóstakrabbamein - innkirtla meðferð - fulvestrant er ætlað fyrir meðferð estrógen viðtaka jákvætt, á staðnum háþróaður eða brjóstakrabbamein í tíðahvörf konur:ekki áður meðhöndluð með annarra meðferð, eðameð sjúkdómur bakslag eða á eftir viðbótar anti-estrógen meðferð, eða sjúkdóms á andestrógeni meðferð.

Europese Unie - IJslands - EMA (European Medicines Agency)

mylan pharmaceuticals limited - gefitinib - krabbamein, lungnakrabbamein - antineoplastic agents, protein kinase inhibitors - gefitinib mylan er ætlað eitt og sér fyrir meðferð fullorðinn sjúklinga með staðnum háþróaður eða sjúklingum ekki lítið klefi lungnakrabbamein (nsclc) með því að virkja stökkbreytingar egfr‑tk.

Europese Unie - IJslands - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirus sýkingar - veirueyðandi lyf til almennrar notkunar - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). Íhuga ætti að opinbera leiðsögn á réttri notkun af veirum.

IJsland - IJslands - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - valaciclovirum hýdróklóríð - filmuhúðuð tafla - 500 mg

Europese Unie - IJslands - EMA (European Medicines Agency)

helsinn birex pharmaceuticals ltd. - chlormethine - mycosis fungoides - Æxlishemjandi lyf - ledaga er ætlað til staðbundinnar meðhöndlunar á t-frumu eitilæxli (mycosis fungoides-type t-cell lymphoma) hjá fullorðnum sjúklingum.

Europese Unie - IJslands - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - sýklalyf fyrir almenn nota, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Europese Unie - IJslands - EMA (European Medicines Agency)

mylan pharmaceuticals limited - prasugrel besilate - myocardial infarction; acute coronary syndrome; angina, unstable - blóðþurrðandi lyf - prasugrel mylan, sam gefið með asetýlsalisýlsýru (asa), er ætlað til að fyrirbyggja atherothrombotic atburðum í fullorðinn sjúklinga með bráð kransæðastíflu (ég. óstöðug hjartslætti, non-l hækkun kransæðastíflu [ha/nstemi] eða l hækkun kransæðastíflu [st-hækkun]) gangast undir aðal eða frestað um kransæðastíflu afskipti (náist á ný).

Europese Unie - IJslands - EMA (European Medicines Agency)

mylan pharmaceuticals limited - acetylsalicylic acid, clopidogrel hydrogen sulfate - acute coronary syndrome; myocardial infarction - blóðþurrðandi lyf - eftir að/asetýlsalisýlsýru mylan er ætlað fyrir efri fyrirbyggja atherothrombotic atburðum í fullorðinn sjúklinga þegar þú tekur bæði eftir og asetýlsalisýlsýru (asa). eftir að/asetýlsalisýlsýru mylan er fastur-skammt samsetning lyf fyrir áframhaldandi meðferð í:ekki l hækkun bráð kransæðastíflu (óstöðug hálsbólgu eða ekki q-bylgja kransæðastíflu) þar á meðal sjúklinga gangast undir stoðneti staðsetningar eftir stungið kransæðastíflu interventionst hækkun, bráð myndun stíflufleygs í læknisfræðilega sjúklingum rétt fyrir segaleysandi meðferð.

Europese Unie - IJslands - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Europese Unie - IJslands - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.